Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

"Vascular access complications represent a significant healthcare problem, and we were impressed by the market opportunity for PRT-201 and with the quality of Proteon's team," said Dr. Steven St. Peter, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Proteon."

About PRT-201

PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown to cause dilation of segments of arteries and veins following topical intraoperative application in animals. Vessel dilation and increased blood flow through the fistula may decrease AVF maturation failure rates. Improved maturation rates may lead to fewer corrective surgical procedures, hospitalizations, lower costs, and less suffering for dialysis patients. PRT-201 also will be studied for its ability to prolong the patency of arteriovenous grafts (AVGs).

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit www.proteontherapeutics.com.

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.4 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... "Pete" Petit, has been awarded the Lifetime Achievement Award ... Program. The Entrepreneur Of The Year ...
(Date:6/29/2015)... 2015 According to a new market ... Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), by ... - Global Forecast to 2020", published by MarketsandMarkets, the global ... from $107.56 Million in 2015, at a CAGR of 17.89%. ... 67 F igures spread through 125 ...
(Date:6/29/2015)... Calif. , June 29, 2015   Veracyte, ... company pioneering the field of molecular cytology, today announced ... News Group,s prestigious Top Workplaces list for the second ... Workplace winners based solely on an annual survey of ... and honored that the degree to which Veracyte values ...
(Date:6/29/2015)... , June 29, 2015 ... and medical information products and services, today announced the ... According to the 2014 Journal Citation Reports® (JCR) published ... Impact Factors increase from 2013 to 2014, ahead of ... occupied the top rank in 62 subject categories, up ...
Breaking Biology Technology:EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3
... 27 Following the successful acquisition of,Drug Development ... organization, announced today that it has fully,integrated its ... branded as,Chiltern Early Phase., Chiltern Early Phase ... pharmaceutical industry via its two well established units ...
... 26 Based on its recent analysis,of the ... presents Kionix, Inc. with the 2008 Global Frost ... a leadership position,in analog output accelerometer products, and ... KXSC7 accelerometer release, a natural extension of,its product ...
... Industries is,pleased to announce the addition of long ... newest member on their Board of Directors., ... Mr.,Skiven oversaw during his 15 years as Executive ... logical that he would join the board of ...
Cached Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 3Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 4GM Exec Joins Bio-Reaction Industries' Board of Directors 2
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
(Date:6/23/2015)... Minn. , June 23, 2015   ... company that supports the entire spectrum of clinical ... iMedNet ™ , the company,s intuitive, ... been awarded a Silver 2015 Stevie® Award by ... Health Products & Services Website category.  The American ...
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... anti-retroviral therapy) has emerged as an extremely effective HIV ... can never truly eradicate the virus as some HIV ... suberoylanilide hydroxamic acid (SAHA), recently approved as a leukemia ... HIV, making it an attractive candidate to weed out ...
... RICHLAND, Wash. -- Single oxygen atoms dancing on a ... have helped chemists better understand how water splits into ... visualized a chemical reaction that had previously only been ... the chemistry needed to generate hydrogen fuel from water ...
... A new Queen,s University study shows that detergents used to ... toxicity to fish, making it more harmful. "The detergents ... long term because the dispersed oil is diluted and degraded," ... they increase the bioavailability and toxicity of the fuel to ...
Cached Biology News:Dancing 'adatoms' help chemists understand how water molecules split 2Dancing 'adatoms' help chemists understand how water molecules split 3
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
Biology Products: